News & Updates

Show Multimedia Only

DTG/3TC tied to lower steatotic liver disease rates in PLWH

17 Mar 2026 by

Switching to dolutegravir/lamivudine (DTG/3TC) was associated with a significantly lower rate of steatotic liver disease (SLD) compared with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among people living with HIV (PLWH), according to a subgroup analysis of the PASO DOBLE trial presented at CROI 2026.

DTG/3TC tied to lower steatotic liver disease rates in PLWH

17 Mar 2026

Niacinamide lowers CVD risk in dermatology patients

16 Mar 2026

Supplementation with niacinamide appears protective against some cardiovascular events, such as myocardial infarction and cardiac arrest, suggests a study.

Niacinamide lowers CVD risk in dermatology patients

16 Mar 2026

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

16 Mar 2026 by

Treatment with pembrolizumab plus belzutifan results in a significant and clinically meaningful improvement in disease-free survival (DFS) compared with pembrolizumab monotherapy in patients with clear cell renal cell carcinoma (ccRCC) who are at greater risk of recurrence following nephrectomy, results from the phase III LITESPARK-022 study have shown.

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

16 Mar 2026

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

15 Mar 2026 by

The addition of hormone therapy, either short- or long-term, to postoperative radiotherapy (PORT) offers no survival advantage over PORT alone in prostate cancer, especially for men with very low pre-PORT prostate specific antigen (PSA) levels, according to the POSEIDON study.

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

15 Mar 2026

Long-term dupilumab treatment for severe asthma effective in real-world

15 Mar 2026

Patients with severe asthma who receive long-term treatment with dupilumab in real-world settings see sustained improvements in clinical and patient outcomes, with most achieving remission after 2 years, according to interim data of the ProVENT study.

Long-term dupilumab treatment for severe asthma effective in real-world

15 Mar 2026

COVID shots moderately effective against postacute sequelae

14 Mar 2026 by

COVID-19 vaccination appears to be moderately effective at preventing lingering symptoms following SARS-CoV-2 infection, and this effectiveness may increase with the number of doses administered, according to a meta-analysis.

COVID shots moderately effective against postacute sequelae

14 Mar 2026

Bisoprolol, but not verapamil, eases peak oxygen consumption in nonobstructive HCM

13 Mar 2026

Peak oxygen consumption (pVO2) in patients with nonobstructive hypertrophic cardiomyopathy (HCM) is reduced following treatment with the beta-blocker bisoprolol but remains unchanged with the calcium-channel blocker verapamil, reports a study.

Bisoprolol, but not verapamil, eases peak oxygen consumption in nonobstructive HCM

13 Mar 2026

Metformin, UDCA no better than placebo in treating long COVID symptoms

13 Mar 2026 by

Treatment with either metformin or ursodeoxycholic acid (UDCA) falls short of improving recovery from postacute sequalae of SARS-CoV-2 infection (PASC), a study has shown.

Metformin, UDCA no better than placebo in treating long COVID symptoms

13 Mar 2026

IVP levetiracetam safe for paediatric patients

13 Mar 2026

The incidence of adverse events does not significantly differ between paediatric patients who received undiluted levetiracetam intravenous push (IVP) over 5 min and those who received the antiepileptic drug (AED) as an IV piggyback (IVPB), a study has shown.

IVP levetiracetam safe for paediatric patients

13 Mar 2026

Enzalutamide plus radium-223 boosts OS in mCRPC

13 Mar 2026 by

Adding enzalutamide to radium-223 significantly improves overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with enzalutamide alone, according to the phase III EORTC 1333/PEACE-3 trial presented at ASCO GU 2026.

Enzalutamide plus radium-223 boosts OS in mCRPC

13 Mar 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

DTG/3TC tied to lower steatotic liver disease rates in PLWH

DTG/3TC tied to lower steatotic liver disease rates in PLWH

Niacinamide lowers CVD risk in dermatology patients

Niacinamide lowers CVD risk in dermatology patients

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

Pembrolizumab-belzutifan combo improves disease-free survival in clear cell renal cell carcinoma

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

No meaningful benefit to adding hormone therapy to PORT in prostate cancer

Long-term dupilumab treatment for severe asthma effective in real-world

Long-term dupilumab treatment for severe asthma effective in real-world

COVID shots moderately effective against postacute sequelae

COVID shots moderately effective against postacute sequelae

Bisoprolol, but not verapamil, eases peak oxygen consumption in nonobstructive HCM

Bisoprolol, but not verapamil, eases peak oxygen consumption in nonobstructive HCM

Metformin, UDCA no better than placebo in treating long COVID symptoms

Metformin, UDCA no better than placebo in treating long COVID symptoms

IVP levetiracetam safe for paediatric patients

IVP levetiracetam safe for paediatric patients

Enzalutamide plus radium-223 boosts OS in mCRPC

Enzalutamide plus radium-223 boosts OS in mCRPC